Category

Home Page

Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

By | Home Page, Uncategorized | No Comments

Seattle, WA

Sound Pharmaceuticals, Inc., (SPI) is pleased to announce that it has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The CFFT development award will support the initial testing of SPI-1005 in people with CF who are receiving tobramycin for the treatment of acute pulmonary exacerbations or lung infections. A leading side effect of tobramycin involves damage to the inner ear and is called ototoxicity. The Phase 1b STOP Ototoxicity clinical trial will examine the incidence and severity of hearing loss, tinnitus, dizziness or vertigo due to IV tobramycin treatment. SPI-1005 is a novel oral drug that is being developed to reduce the incidence and severity of sensorineural hearing loss and tinnitus in several disease states including ototoxicity, noise and Meniere’s disease.
Read More

Sound Pharmaceuticals and DoD collaborate on new hearing loss guidance

By | Home Page, Uncategorized | No Comments

Seattle, WA

Sound Pharmaceuticals, a pioneer in the development of novel drug treatments for inner ear disease, announced today that Jonathan Kil, MD, Co-Founder and Chief Medical Officer, is a co-author on two publications from the Department of Defense’s Hearing Center of Excellence (HCE). The HCE is focused on the prevention, diagnosis, mitigation, treatment, and rehabilitation of hearing loss. HCE is congressionally directed to partner with the Department of Veterans Affairs (VA), and other organizations that support the study of auditory injury. The papers are part of a series of new guidance documents from the HCE published in the September issue of Otology & Neurotology, a leading otolaryngology journal. Read More

Sound Pharmaceuticals and Oxford collaborate on a new treatment for bipolar disorder

By | Home Page | No Comments
Seattle, WA and Oxford, England

 
Sound Pharmaceuticals (SPI) will collaborate with the University of Oxford on a Phase 2 clinical trial to test SPI-1005 for the treatment of bipolar disorder. Bipolar disorder is a psychiatric illness that involves both periods of mania and depression, and affects approximately one percent of adults worldwide. Unfortunately, patients have relatively few treatment options, often involving drugs such as lithium, which has significant side effects. Read More

David Guyer visionary biotech leader joins Sound Pharmaceuticals

By | Home Page | No Comments
Sound Pharmaceuticals is pleased to announce that David Guyer, MD has joined the company as a strategic advisor. Dr. Guyer is an accomplished academic ophthalmologist and an industry leader in the area of vision loss research and retinal drug development. Dr. Guyer is currently the Co-Founder, Chief Executive Officer and Chairman of Ophthotech which he began in 2007. As CEO, Dr. Guyer raised more than $350 million in financing including a $192 million IPO in 2013 and has advanced the lead program into Phase 3 clinical trials.

Read More

The World Health Organization reports 1.1 Billion teens and young adults at risk

By | Home Page | No Comments

(CNN) “Hey dude — can you turn your music down?”

If anyone says this to you while you’re wearing your earbuds, take note: You are probably endangering your hearing.

More than one billion teens and young adults are at risk of losing their hearing, according to WHO (that’s the World Health Organization, not the rock band).

It’s not just old folks who suffer hearing loss. Just by listening to music at what you probably think is a normal level, or hanging out in loud bars, nightclubs and music and sporting events, you can permanently damage your hearing.

Full Article here: 

http://www.cnn.com/2015/03/06/health/hearing-loss-loud-music/